首页> 外文期刊>Transfusion medicine reviews >Home Delivery: Transfusion Services When and Where They Are Nee de d
【24h】

Home Delivery: Transfusion Services When and Where They Are Nee de d

机译:送货上门:输血服务何时何地

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Home blood product transfusion has been utilized around the world in various forms over the past few decades. There is current interest in decentralizing hospital care to improve patient independence and convenience, minimize cost to the health service, and to prevent nosocomial infection, especially with the recent COVID-19 pandemic. The transition to "hospital in the home" is occurring across the healthcare sector driven by aims to improve patient outcomes and patient satisfaction, capacity pressures in the acute care sector, and most recently due to concerns regarding infectious disease transmission in hospital settings. This review explores the published literature on home red cell and platelet transfusions, and where the literature is limited, also considered data from subcutaneous immunoglobulin studies. Current published experience on red cell and platelet transfusion at home has identified benefits to the patient and health service, with further studies needed to quantify improvement in quality of life and health -related outcomes. Safety concerns may be a perceived barrier to implementation of home transfusion, however current published data suggests serious adverse reactions are rare. Cost-effectiveness data for home transfusion are very limited and a key area for future research. Home transfusion has the potential to benefit from newer technologies, such as portable/remote monitoring and electronic patient identifiers.(c) 2022 Elsevier Inc. All rights reserved.
机译:在过去的几十年里,家庭血液制品输注在世界各地以各种形式被使用。目前,人们有兴趣分散医院护理,以提高患者的独立性和便利性,最大限度地降低卫生服务成本,并预防院内感染,尤其是在最近的 COVID-19 大流行的情况下。向“家庭医院”的过渡正在整个医疗保健部门发生,其驱动力是改善患者预后和患者满意度,急症护理部门的能力压力,以及最近由于对医院环境中传染病传播的担忧。本综述探讨了已发表的关于家庭红细胞和血小板输注的文献,在文献有限的情况下,也考虑了皮下免疫球蛋白研究的数据。目前已发表的关于在家输注红细胞和血小板的经验已经确定了对患者和卫生服务的益处,需要进一步的研究来量化生活质量和健康相关结果的改善。安全问题可能是实施家庭输血的障碍,但目前公布的数据表明,严重的不良反应很少见。家庭输血的成本效益数据非常有限,是未来研究的关键领域。家庭输血有可能受益于较新的技术,例如便携式/远程监测和电子患者标识符。(c) 2022 爱思唯尔公司保留所有权利。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号